Design, characterization and antimalarial efficacy of PEGylated galactosylated nano lipid carriers of primaquine phosphate
Source abstract
Abstract
This study was aimed to design and optimize primaquine phosphate (PQ) loaded nanostructured lipid carriers (NLCs) using response surface methodology. The optimized NLCs were evaluated for various physical and morphological characterizations. The in vitro studies for drug release showed that PQ loaded NLCs had a sustained release up to 72 h and the stability studies confirmed that the PQ-NLCs were stable for 90 d at 4 °C and 25 °C. In vitro erythrocyte toxicity revealed that PQ-NLCs were less toxic than the pure drug. In vitro parasite growth inhibition assay showed an IC50 value of 71.11 ± 6.47 ng/ml for the 3D7 Plasmodium falciparum (CQ sensitive) strain and 263.86 ± 5.68 ng/ml for RKL9 P. falciparum (CQ resistant) strain for the PQ-NLCs. Enhanced parasitaemia suppression of 99.46% at 2 mg/kg/d, a better suppression of parasitaemia of about 28% more than pure drug and a higher survivality rate of 66.66% even after the 35th day was observed for the PQ loaded NLCs. Also from the comparative fluorescent imaging study, it was clearly observed that accumulation of PQ-NLCs in the liver was more that of the pure drug. These results clearly indicated that the limitations of antimalarial drug PQ can be overcomed by loading it into the NLCs.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, JSS College of Pharmacy, Jagadguru Sri Shivarathreeswara University, Ootacamund, India;
Department of Biotechnology and Bioinformatics, School of life Sciences, University of Hyderabad, Hyderabad, India;
National Institute of Malaria Research (ICMR), Dwarka, India
References (44)
Show source-provided references
1. 10.1016/j.ejmech.2008.08.01110.1016/j.ejmech.2008.08.011 ↗
2. Hill DR · Am J Trop Med Hyg · 2006 · 75 · 40210.4269/ajtmh.2006.75.402 ↗
3. 10.1186/1475-2875-10-35110.1186/1475-2875-10-351 ↗
4. 10.1016/S1471-4922(03)00005-910.1016/S1471-4922(03)00005-9 ↗
5. 10.1016/j.ijpharm.2007.06.03510.1016/j.ijpharm.2007.06.035 ↗
6. 10.1155/2013/38218410.1155/2013/382184 ↗
7. 10.1016/j.ejpb.2005.07.00410.1016/j.ejpb.2005.07.004 ↗
8. 10.3109/08982104.2012.66265310.3109/08982104.2012.662653 ↗
9. Zani B · Cochrane Libr · 2014 · CD010927
10. 10.1016/j.colsurfb.2013.09.03010.1016/j.colsurfb.2013.09.030 ↗
11. 10.1016/j.ijpharm.2013.12.00610.1016/j.ijpharm.2013.12.006 ↗
12. 10.1002/jps.2271110.1002/jps.22711 ↗
13. 10.1016/j.colsurfb.2015.12.03310.1016/j.colsurfb.2015.12.033 ↗
14. 10.3109/10717544.2014.88599910.3109/10717544.2014.885999 ↗
15. 10.4103/0973-8398.13492110.4103/0973-8398.134921 ↗
16. 10.1016/S0939-6411(02)00130-310.1016/S0939-6411(02)00130-3 ↗
17. 10.1016/j.molliq.2017.01.10710.1016/j.molliq.2017.01.107 ↗
18. 10.1016/j.ijpharm.2015.07.01310.1016/j.ijpharm.2015.07.013 ↗
19. 10.1016/S0928-0987(01)00095-110.1016/S0928-0987(01)00095-1 ↗
20. Peppas N. · Pharm Acta Helv · 1985 · 60 · 110
21. 10.1016/j.ijpharm.2008.07.03210.1016/j.ijpharm.2008.07.032 ↗
22. 10.1016/S0031-6865(99)00003-510.1016/S0031-6865(99)00003-5 ↗
23. 10.1645/0022-3395(2005)091[0484:HMPICC]2.0.CO;210.1645/0022-3395(2005)091[0484:HMPICC]2.0.CO;2 ↗
24. 10.1186/1475-2875-8-2610.1186/1475-2875-8-26 ↗
25. 10.1016/0014-4894(65)90012-310.1016/0014-4894(65)90012-3 ↗
26. Borhade V · Int J Pharm · 2012 · 431 · 1):149
27. 10.1080/00034983.2001.1181361410.1080/00034983.2001.11813614 ↗
28. 10.3109/10717544.2015.108440010.3109/10717544.2015.1084400 ↗
29. 10.1016/j.ejpb.2006.10.01410.1016/j.ejpb.2006.10.014 ↗
30. 10.1016/j.colsurfa.2010.09.03010.1016/j.colsurfa.2010.09.030 ↗
31. 10.1016/j.colsurfa.2007.08.00510.1016/j.colsurfa.2007.08.005 ↗
32. 10.1016/j.colsurfa.2013.07.02210.1016/j.colsurfa.2013.07.022 ↗
33. Bellissent-Funel M. · Hydrat Process Biol · 1999 · 305 · 115
34. 10.1016/j.jsps.2012.11.00510.1016/j.jsps.2012.11.005 ↗
35. 10.1016/j.ijbiomac.2015.12.07710.1016/j.ijbiomac.2015.12.077 ↗
36. Raj R · Artif Cells Nanomed Biotechnol · 2016 · 44 · 143410.3109/21691401.2015.1036997 ↗
37. 10.1208/pt080408310.1208/pt0804083 ↗
38. 10.1016/S0378-5173(03)00383-110.1016/S0378-5173(03)00383-1 ↗
39. 10.1016/S0928-0987(99)00071-810.1016/S0928-0987(99)00071-8 ↗
40. 10.1155/2011/12046210.1155/2011/120462 ↗
41. 10.1086/34021310.1086/340213 ↗
42. 10.1111/j.1462-5822.2011.01741.x10.1111/j.1462-5822.2011.01741.x ↗
43. Soniran O · Malar Res Treat · 2012 · 2012 · 960758
44. 10.1016/j.biomaterials.2008.09.01410.1016/j.biomaterials.2008.09.014 ↗